|
業務類別
|
Biotechnology |
|
業務概覽
|
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liverfibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
| 公司地址
| 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 567-7770 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.gyretx.com |
| 員工數量
| 625 |
| Dr. Ying Luo, PhD |
Director, Chief Executive Officer and President |
-- |
04/05/2026 |
| Mr. Weiguo Ye |
Chief Operating Officer |
美元 196.95K |
27/04/2026 |
| Mr. Thomas Eastling |
Chief Financial Officer |
-- |
04/05/2026 |
|
|
| Mr. Ping Zhang |
Chairman of the Board |
04/05/2026 |
| Dr. Ying Luo, PhD |
Director, Chief Executive Officer and President |
04/05/2026 |
| Mr. Rodney L. Nussbaum |
Independent Director |
27/04/2026 |
| Dr. Gordon G. Carmichael, PhD |
Independent Director |
27/04/2026 |
| Dr. Renate Parry, PhD |
Independent Director |
27/04/2026 |
| Dr. David M. Epstein, PhD |
Independent Director |
27/04/2026 |
| Dr. Dan Weng, M.D. |
Independent Director |
27/04/2026 |
|
|
|
|
